Release date: 10 December 2020
Promoter – Financial Intermediary
ATRIVA THERAPEUTICS GMBHLocation
Description
Financing the borrower's research and development (R&D) and clinical trials related to its novel antiviral drug ATR-002, which will target influenza and other respiratory viruses, including SARS-CoV-2.
Objectives
The project supports a biotech company to develop a novel antiviral medicinal product for influenza and other respiratory viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The eligible investment plan includes R&D and related expenses.
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 24 million
Total cost (Approximate amount)
EUR 30 million
Environmental aspects
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority; thus, the project is not covered by the EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Status
Signed - 16/10/2020
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).